A multi-center, open label, crossover designed prospective study evaluating the effects of lipid lowering treatment on steroid synthesis in patients with Type 2 diabetes (MODEST Study)

dc.authorid0000-0001-8454-4547en_US
dc.authorid0000-0002-7361-8181
dc.authorid0000-0001-5642-6498
dc.contributor.authorKanat, Mustafa
dc.contributor.authorSerin, Erdinç
dc.contributor.authorTunçkale, Aydın
dc.contributor.authorYıldız, O.
dc.contributor.authorŞahin, Sevgi
dc.contributor.authorArınç, Hüseyin
dc.contributor.authorKaragöz, Yalçın
dc.date.accessioned2021-06-23T19:26:04Z
dc.date.available2021-06-23T19:26:04Z
dc.date.issued2009
dc.departmentBAİBÜ, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümüen_US
dc.departmentBAİBÜ, Tıp Fakültesi, Temel Tıp Bilimleri Bölümü
dc.departmentBAİBÜ, Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümü
dc.departmentBAİBÜ, İktisadi ve İdari Bilimler Fakültesi, İşletme Bölümü
dc.description.abstractObjective: It has been suggested that lipid-lowering treatment with the use of statins adversely affects the steroid hormones. However, the safety of lipid lowering treatment targeting very low levels of LDL with respect to the steroid hormones has not been established. Research design and methods: A prospective, randomized, multicenter trial was conducted involving 98 patients. The patients were randomized into 2 groups: group-I received 10 mg of atorvastatin plus 10 mg of ezetimibe and group-II 80 mg of atorvastatin for the first 3 months. After crossover, the first group received 80 mg of atorvastatin and the second group 10 mg of atorvastatin plus 10 mg of ezetimibe for the following 3 months. Cortisol, DHEAS, testosterone, and estradiol levels were measured at the enrollment and at the end of the 1(st), 2(nd), 3(rd), and 6(th) months. Results: Along with a decrease in LDL level, the levels of DHEAS, testosterone, and estradiol decreased in both groups (p<0.001). While cortisol levels were maintained in the group given 10 mg of atarvastatin plus 10 mg of ezetimibe, it decreased significantly after the crossover to 80 mg of atorvastatin (p<0.001). The group initially given 80 mg of atorvastatin measured a lower level of cortisol for the first 3 months and it returned to normal levels after switching to 10 mg of atorvastatin plus 10 mg of ezetimibe. Conclusion: Eighty milligrams of atorvastatin decreased all adrenal and gonadal steroids, where,is 10 mg of ezetimibe combined with 10 mg of atorvastatin had at least no impact on cortisol levels. (J. Endocrinol. Invest. 32: 852-856, 2009) (C)2009, Editrice Kurtisen_US
dc.identifier.doi10.1007/BF03345757
dc.identifier.endpage856en_US
dc.identifier.issn0391-4097
dc.identifier.issn1720-8386
dc.identifier.issue10en_US
dc.identifier.pmid19783896en_US
dc.identifier.scopus2-s2.0-73449106324en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage852en_US
dc.identifier.urihttps://doi.org/10.1007/BF03345757
dc.identifier.urihttps://hdl.handle.net/20.500.12491/6404
dc.identifier.volume32en_US
dc.identifier.wosWOS:000274444900011en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.institutionauthorKanat, Mustafa
dc.institutionauthorSerin, Erdinç
dc.institutionauthorArınç, Hüseyin
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.relation.ispartofJournal Of Endocrinological Investigationen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAtorvastatinen_US
dc.subjectLipid-lowering Treatmenten_US
dc.subjectSteriod Hormonesen_US
dc.subjectVery Low LDLen_US
dc.titleA multi-center, open label, crossover designed prospective study evaluating the effects of lipid lowering treatment on steroid synthesis in patients with Type 2 diabetes (MODEST Study)en_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
mustafa-kanat.pdf
Boyut:
105.23 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam metin/Full text